Akebia Therapeutics, Inc. (AKBA) Dividend History

Company News

• Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025

  Akebia Therapeutics, a biopharmaceutical company focused on kidney disease, announced that it will present three posters at the European Renal Association Congress 2025.

  GlobeNewswire Inc.
• AVEROA Receives Positive Opinion from the European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD)

  Averoa, a biopharmaceutical company, has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for its oral therapy XOANACYL, which is used to treat chronic kidney disease.

  GlobeNewswire Inc.
• Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

  Akebia Therapeutics, a biopharmaceutical company, announced the pricing of its $50 million public offering of 25 million shares of common stock at $2 per share. The offering is expected to close on March 21, 2025.

  GlobeNewswire Inc.
• $10.7 Billion Healthcare Mobile Robots Market Outlook, 2030 by Type, End Use and Region - Akebia Therapeutics, ABB, Aethon, Omron Corp., and Amazon Lead the Competition

  The global healthcare mobile robots market is expected to grow from $4.45 billion in 2024 to $10.7 billion by 2030, driven by technological advancements, shortage of skilled healthcare staff, and rising healthcare expenditures. North America is the dominant market, supported by favorable government initiatives and a developed healthcare infrastructure.

  GlobeNewswire Inc.

  Featured Companies: AMZN
• Unicycive Therapeutics Announces Initial Positive Patient - GlobeNewswire

  Unicycive Therapeutics announced positive patient satisfaction results from a clinical trial of its phosphate binder drug, Oxylanthanum Carbonate (OLC). Patients preferred OLC over their prior phosphate binder therapy, and the pill burden was reduced by half.

  GlobeNewswire Inc.

  Featured Companies: UNCY